Dual Antiplatelet Therapy After Acute Coronary Syndrome

episode

JAMA Clinical Reviews not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

A.I. Safety Goes Mainstream + a ‘Hard Fork’ Exit AMA 1h 25m · 18 Sep 2026 · Hard Fork

Layoffs at the Kansas City Star will hurt local communities 15 min · 18 Sep 2026 · Kansas City Today

AWP: Beyond the Exam Room: Purpose, Myopia, and Population Health 54 min · 17 Sep 2026 · EyeCode Media

Planning Commission Meeting - Sep 17, 2026 1h 11m · 17 Sep 2026 · Leesburg Planning Commission

Heritage Commission - Sep 14, 2026 1h 57m · 17 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Historic District Review Committee - Sep 14, 2026 1h 36m · 17 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Report any issue

Source

Recorded20 Apr 2021

Publisherjamaclinicalreviews.libsyn.com ↗

Handlerec:7722696

Show notes

Dual antiplatelet therapy, typically aspirin and an oral P2Y12 receptor inhibitor (clopidogrel, prasugrel, ticagrelor, cangrelor), reduces adverse events after acute coronary syndrome (ACS) but choice of agent and optimal duration may be patient-specific. Umair Khalid, MD, a cardiologist at the Baylor School of Medicine in Houston, discusses how to use these agents in management of ACS. Related Article(s): Oral Antiplatelet Therapy After Acute Coronary Syndrome

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in